ClinicalTrials.gg

Program

as01e

A development code. Also written as “40 µg gE-gI/AS01E”, “80 µg gE-gI/AS01E” and “160 µg gE-gI/AS01E”.

Its studies are mostly in Malaria · Herpes Genitalis, led by GlaxoSmithKline.

Furthest: phase 2, since May 15, 20174 company-led studies, 1 open or runningNext primary completion: Apr 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline41 open or runningphase 2since May 15, 2017May 15, 2017Apr 23, 2027phase 2 · NCT07036159

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2017First study: phase 2 study in MalariaFirst studyNCT03162614 · 154 enrolled · United States
  2. Sep 7, 2017Phase 2 study in MalariaNCT03276962 · 1,500 enrolled · Ghana, Kenya
  3. Mar 4, 2022Phase 2 study in Herpes SimplexNCT05298254 · 504 enrolled · United States, Australia, Belgium and more
  4. Jun 16, 2025Phase 2 study in MalariaNCT07036159 · 238 planned · Rwanda

Ahead

  1. Apr 23, 2027Primary completion: phase 2 study in MalariaNCT07036159

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07036159Malaria · Rwanda2RecruitingApr 23, 2027238
NCT05298254Herpes Simplex · United States, Australia, Belgium and more2CompletedJun 12, 2025504
NCT03276962Malaria · Ghana, Kenya2CompletedNov 4, 20191,500
NCT03162614Malaria · United States2CompletedJul 9, 2018154

How it is read

Names in the registry

  • “40 µg gE-gI/AS01E”, 1 entry
  • “80 µg gE-gI/AS01E”, 1 entry
  • “160 µg gE-gI/AS01E”, 1 entry
  • “RTS,S/AS01E vaccine”, 1 entry
  • “RTS,S/AS01E (Full dose)”, 1 entry

Codes read as this program: AS01E.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.